Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Canada
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Samuraciclib + Gemcitabine & Nab-Paclitaxel — 1 site
- TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
[68Ga]Ga-NNS309 · [177Lu]Lu-NNS309 — 29 sites
- TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 131 sites
- TRIALPHASE1RECRUITING
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
M0324 · M0324 · Pembrolizumab — 5 sites
- TRIALPHASE2RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AZD0901 · 5-Fluorouracil · Leucovorin — 52 sites
- TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
68Ga-NNS309 · 177Lu-DFC413 — 8 sites
- TRIALPHASE1RECRUITING
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
CX-5461 — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
BOLD-100 +/- FOLFOX Chemotherapy (Arm VII) · BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) — 24 sites
- TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 91 sites
- TRIALPHASE1NOT_YET_RECRUITING
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
ATRA · Arsenic Trioxide (ATO) · Gemcitabine — 1 site
- TRIALPHASE1RECRUITING
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
BCA101 · Pembrolizumab — 20 sites
- TRIALPHASE1RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
LY3962673 · Cetuximab · Gemcitabine — 52 sites
- TRIALNARECRUITING
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Genetic testing · Optional biopsy · Tissue collection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Sacituzumab tirumotecan · Fluorouracil (5-FU) · Leucovorin (LV) or levoleucovorin — 55 sites
- TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALNARECRUITING
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Irreversible electroporation (NanoKnife® ) — 2 sites
- TRIALPHASE4RECRUITING
Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
enoxaparin/tinzaparin/dalteparin — 5 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALNARECRUITING
EUS-CPN With and Without Bupivacaine
EUS-CPN without bupivacaine · EUS-CPN with bupivacaine — 1 site
- TRIALPHASE1RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Azirkitug · Budigalimab · Bevacizumab — 48 sites
- TRIALNARECRUITING
Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
Pancreatic resection and non-anatomic liver resections. — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523 · Gemcitabine · Nab-Paclitaxel — 8 sites
- TRIALPHASE1RECRUITING
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
M7437 · M7437 — 9 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 58 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
daraxonrasib · gemcitabine · nab-paclitaxel — 49 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 228 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.